08.06.25 -- How To Be A Policy Advocate For Biotech

Projected to grow 16.1% annually through 2030, eCOA solutions are booming. Uncover the top five myths and misconceptions about eCOAs in 2025 so your clinical teams can make evidence-based decisions.

Delve into the logistical and financial obstacles faced by stakeholders in clinical trials, highlighting the need for balance in improving the participant experience while managing operational efficiency.

Explore the pros and cons of marketed amorphous solid dispersions with so-far unpublished data as well as a green alternative to ASDs: best-in-class nanotechnology to manufacture nanocrystals.

As recombinant protein-based products accelerate toward IND, reliable process development methods are critical to meet demand. Review case studies to learn how expedited timelines can be achieved.

The obesity drug development landscape is rapidly evolving, but despite this promising trajectory, significant barriers in patient recruitment and retention persist.